Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?Zacks Investment Research • 04/09/21
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMDGlobeNewsWire • 04/07/21
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma GroupGlobeNewsWire • 04/06/21
Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond OncologyBusiness Wire • 03/30/21
Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of DirectorsBusiness Wire • 03/18/21
Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare ConferenceBusiness Wire • 03/11/21
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 03/11/21
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of CancerBusiness Wire • 01/26/21
Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare ConferenceBusiness Wire • 11/24/20
Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.Business Wire • 11/20/20
Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare ConferenceBusiness Wire • 11/12/20
Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual MeetingBusiness Wire • 11/09/20
Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 11/05/20
Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual MeetingBusiness Wire • 10/14/20
Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules CapitalBusiness Wire • 10/01/20
Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020Business Wire • 09/14/20
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid TumorsBusiness Wire • 09/10/20
Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718Business Wire • 09/02/20
Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular EdemaBusiness Wire • 09/01/20
Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 08/05/20